Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: Elstrom, Rebecca L.; Ruan, Jia; Christos, Paul J.; Martin, Peter; Lebovic, Daniel; Osborne, Joseph; Goldsmith, Stanley; Greenberg, June; Furman, Richard R.; Avram, Anca; Putman, Ryan; Chapman, Erica; Mazumdar, Madhu; Griffith, Kent; Coleman, Morton; Leonard, John P.; Kaminski, Mark S.
• Is Part Of: Leukemia & lymphoma. Volume 56:Issue 2(2015:Feb.)
• Page Start: 342
• Page End: 346
• Publication Date: 2015-02
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2014.914195
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>Radioimmunotherapy (RIT) is effective treatment for indolent non-Hodgkin lymphomas (NHLs), but response durations are usually limited, especially in aggressive NHL. We hypothesized that administration of bortezomib as a radiosensitizer with RIT would be tolerable and improve efficacy in NHL. This phase 1 dose-escalation study evaluated escalating doses of bortezomib combined with ¹³¹I-tositumomab in patients with relapsed/refractory NHL. Twenty-five patients were treated. Treatment was well tolerated, with primarily hematologic toxicity. The maximum tolerated dose (MTD) was determined to be 0.9 mg/m² bortezomib, in combination with a standard dose of 75 cGy ¹³¹I-tositumomab. Sixteen patients responded (64%), including 44% complete responses (CRs), with 82% CR in patients with follicular lymphoma (FL). At a median follow-up of 7 months, median progression-free survival was 7 months, and seven of 11 patients with FL remained in remission at a median of 22 months. In conclusion, bortezomib can be safely administered in combination with ¹³¹I-tositumomab with promising response rates.</p> </abstract>